Sign in
4

Changes in Ownership

Syndax Pharmaceuticals Inc Filed Acc 0001562180-22-001081

Options or other derivatives

  • Chief Executive Officer acquired 325,000 shares (grant or award)

From the SEC's structured data for this filing

Trades in this filing

Metzger Michael A · Chief Executive Officer

Table II: Derivative

1 line
Date Transaction Shares Price Value Owned after D/I
2022-02-02 Grant or award : show line 1 in the form Stock Options (Right to buy) +325,000 $15.79 $5,131,750 325,000 D
Loading xslF345X03/primarydocument.xml…